<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425073</url>
  </required_header>
  <id_info>
    <org_study_id>40461-B</org_study_id>
    <nct_id>NCT01425073</nct_id>
  </id_info>
  <brief_title>Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya</brief_title>
  <official_title>Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both antiretroviral therapy (ART) and prevention of opportunistic infections (OIs) have been
      associated with significantly decreased mortality in HIV-infected individuals.
      Trimethoprim-sulfamethoxazole (TMP/SMZ), also known as bactrim, is a common antibiotic and
      used as prophylaxis for OIs. For countries with high prevalence of HIV and limited health
      infrastructure, the WHO endorses universal TMP/SMZ for all HIV-infected individuals. Notably,
      these guidelines were created prior to the scale-up of ARTs. Following ART and subsequent
      immune recovery, TMP/SMZ may no longer be required. In the US and Europe, for example,
      TMP/SMZ is discontinued after patients show evidence of immune recovery. Therefore, we
      propose a prospective randomized trial among HIV infected individuals on ART with evidence of
      immune recovery (ART for &gt; 18mo and CD4 &gt;350 cells/mm3) to determine whether continued
      TMP/SMZ prophylaxis confers benefits in decreasing morbidity (malaria, pneumonia, diarrhea),
      mortality, CD4 count maintenance, ART treatment failure and malaria immune responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see summary above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe infectious morbidity (malaria, pneumonia, diarrhea)</measure>
    <time_frame>12 months</time_frame>
    <description>A combined outcome of malaria, pneumonia or severe diarrhea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 count increase</measure>
    <time_frame>12 months</time_frame>
    <description>CD4 count increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ART treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of ART treatment failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>HIV Infections</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Disease Progression</condition>
  <condition>Immune System Diseases</condition>
  <condition>Malaria</condition>
  <condition>Parasitic Diseases</condition>
  <condition>Pneumonia</condition>
  <condition>Diarrhea</condition>
  <condition>Infectious Disorder of Immune System</condition>
  <arm_group>
    <arm_group_label>Stop TMP/SMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care TMP/SMZ prophylaxis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discontinue TMP/SMZ prophylaxis</intervention_name>
    <description>Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study</description>
    <arm_group_label>Stop TMP/SMZ</arm_group_label>
    <other_name>Septrin</other_name>
    <other_name>Septra</other_name>
    <other_name>Cotrimoxazole</other_name>
    <other_name>Bactrim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be at least 18 years of age.

          -  Participants must be willing to participate and give written informed consent.

          -  Participants must be willing and able to return for the scheduled follow-up visits.

          -  Participants must have been on ART for &gt; 18 months.

          -  Participants must have a CD4 count of &gt; 350 cells/mm3.

          -  Participants must not be suspected of ART treatment failure.

        Exclusion Criteria:

          -  Participants must not be pregnant at enrollment (by urine HCG testing).

          -  Participants must not be breastfeeding at the time of enrollment.

          -  Participants must be on first-line ART therapy as defined by Kenyan National
             Guidelines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Polyak, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute/ Department of Medicine, University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Homa Bay District Hospital</name>
      <address>
        <city>Homa Bay</city>
        <state>Nyanza Pronvince</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kombewa District Hospital</name>
      <address>
        <city>Kombewa</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS. 1999 Sep 10;13(13):1687-95. Erratum in: AIDS 2000 Aug 18;14(12):1877.</citation>
    <PMID>10509570</PMID>
  </reference>
  <reference>
    <citation>Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999 May 1;353(9163):1463-8.</citation>
    <PMID>10232311</PMID>
  </reference>
  <reference>
    <citation>Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet. 1999 May 1;353(9163):1469-75. Erratum in: Lancet 1999 Jun 12;353(9169):2078.</citation>
    <PMID>10232312</PMID>
  </reference>
  <reference>
    <citation>Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, Kigozi A, Nakanjako D, Wafula W, Quick R. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004 Oct 16-22;364(9443):1428-34.</citation>
    <PMID>15488218</PMID>
  </reference>
  <reference>
    <citation>Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, Otieno K, Williamson J, Shi YP, Feikin DR, Marston B, Brooks JT, Poe A, Zhou Z, Ochieng B, Mintz E, Slutsker L. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg. 2008 Sep;79(3):320-30.</citation>
    <PMID>18784222</PMID>
  </reference>
  <reference>
    <citation>Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL, Rickenbach M, Flepp M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999 Apr 29;340(17):1301-6.</citation>
    <PMID>10219064</PMID>
  </reference>
  <reference>
    <citation>Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzáles-Lahoz J, d'Arminio Monforte A, Proenca R, Phillips AN, Lundgren JD, Reiss P. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999 Apr 17;353(9161):1293-8.</citation>
    <PMID>10218526</PMID>
  </reference>
  <reference>
    <citation>Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, Shiraishi R, Marston B, Ellerbrock T, Libamba E. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):56-61.</citation>
    <PMID>17972365</PMID>
  </reference>
  <reference>
    <citation>Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, Katabira E, Grosskurth H, Mugyenyi P, Hakim J, Darbyshire JH, Gibb DM, Babiker AG. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010 Apr 10;375(9722):1278-86. doi: 10.1016/S0140-6736(10)60057-8. Epub 2010 Mar 27.</citation>
    <PMID>20347483</PMID>
  </reference>
  <reference>
    <citation>Phillips-Howard PA, Nahlen BL, Kolczak MS, Hightower AW, ter Kuile FO, Alaii JA, Gimnig JE, Arudo J, Vulule JM, Odhacha A, Kachur SP, Schoute E, Rosen DH, Sexton JD, Oloo AJ, Hawley WA. Efficacy of permethrin-treated bed nets in the prevention of mortality in young children in an area of high perennial malaria transmission in western Kenya. Am J Trop Med Hyg. 2003 Apr;68(4 Suppl):23-9.</citation>
    <PMID>12749482</PMID>
  </reference>
  <reference>
    <citation>Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006 Mar 8;295(10):1152-60. Erratum in: JAMA. 2006 Oct 18;296(15):1842.</citation>
    <PMID>16522836</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christina Polyak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Co-Infections</keyword>
  <keyword>Malaria</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

